Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2824950rdf:typepubmed:Citationlld:pubmed
pubmed-article:2824950lifeskim:mentionsumls-concept:C1882726lld:lifeskim
pubmed-article:2824950lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:2824950lifeskim:mentionsumls-concept:C0019602lld:lifeskim
pubmed-article:2824950lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:2824950lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:2824950pubmed:issue21lld:pubmed
pubmed-article:2824950pubmed:dateCreated1987-12-29lld:pubmed
pubmed-article:2824950pubmed:abstractTextPeptide Histidine Isoleucine (PHI) is generally considered a low affinity agonist for Vasoactive Intestinal Peptide (VIP) receptors. In this study, we investigated the presence and characteristics of [125I]PHI binding sites on rat liver membranes. Detergents at nonsolubilizing concentrations (1 mM CHAPS or 0.01% Tween-20) were included in the assay buffer to reduce adsorptive loss of PHI to acceptable levels and permit measurement of PHI-binding to receptors. Under these conditions, binding of PHI to liver membranes was time- and temperature-dependent, reversible and saturable. Unlabeled PHI was 9.7-fold more potent than VIP, and 357-fold more potent than secretin in displacing [125I]-PHI binding. Scatchard analysis suggested the presence of two classes of PHI receptors, with Kd 27 pM and 512 pM. The data from [125I]-PHI and [125I]-VIP binding studies suggested that one class of receptors was PHI-preferring, and the other, equally reactive with PHI and VIP. The concentration of immunoreactive PHI, measured by radioimmunoassay, in blood from the hepatic portal vein of anesthetized rats was 2-fold higher than that from the hepatic vein, suggesting uptake of circulating PHI by the liver.lld:pubmed
pubmed-article:2824950pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:languageenglld:pubmed
pubmed-article:2824950pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:citationSubsetIMlld:pubmed
pubmed-article:2824950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2824950pubmed:statusMEDLINElld:pubmed
pubmed-article:2824950pubmed:monthNovlld:pubmed
pubmed-article:2824950pubmed:issn0024-3205lld:pubmed
pubmed-article:2824950pubmed:authorpubmed-author:PaulSSlld:pubmed
pubmed-article:2824950pubmed:authorpubmed-author:ChouJJlld:pubmed
pubmed-article:2824950pubmed:authorpubmed-author:KubotaEElld:pubmed
pubmed-article:2824950pubmed:issnTypePrintlld:pubmed
pubmed-article:2824950pubmed:day23lld:pubmed
pubmed-article:2824950pubmed:volume41lld:pubmed
pubmed-article:2824950pubmed:ownerNLMlld:pubmed
pubmed-article:2824950pubmed:authorsCompleteYlld:pubmed
pubmed-article:2824950pubmed:pagination2373-80lld:pubmed
pubmed-article:2824950pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:meshHeadingpubmed-meshheading:2824950-...lld:pubmed
pubmed-article:2824950pubmed:year1987lld:pubmed
pubmed-article:2824950pubmed:articleTitleHigh affinity peptide histidine isoleucine-preferring receptors in rat liver.lld:pubmed
pubmed-article:2824950pubmed:affiliationDepartment of Medicine, Oklahoma University Health Sciences Center, Oklahoma City 73190.lld:pubmed
pubmed-article:2824950pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2824950pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2824950pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2824950lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2824950lld:pubmed